Navigation Links
Simplest therapeutic regimen found less effective against HIV

Antiretroviral therapy for treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy in 1996//. More recently, new drugs have been approved, offering added dosing convenience and improved safety profiles, while some previously popular drugs are being used less often as their drawbacks become better defined. Resistance testing is used more commonly in clinical practice and interactions among antiretroviral agents and with other drugs have become more complex. New government guidelines recommend against starting AIDS patients on a popular treatment combination, due to concerns that using two similar drugs can rapidly lead to treatment-resistant strains of HIV.

Therapeutic regimen that combines Videx and Viread with so-called "non-nuke" drugs like Sustiva is one of several treatment groupings that have led to the dramatic turn around against AIDS. In comparison to a litany of pills that HIV patients have to swallow to keep the virus under control, Videx and Viread, are a lot simpler to use, as they have to be taken just once a day.

However, recent studies have shown that HIV quickly grows resistant to the drugs when all three are used at once, possibly because Videx and Viread attack the disease in a like-minded fashion, and so, the Department of Health and Human Services is urging newly diagnosed patients to relinquish therapies that specifically combine these three. The new ‘Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents’ have been published, dated October 6, 2005.

Dr. Roy Gulick, an HIV specialist who helped establish the new guidelines, states that when two similar drugs are used together, they tend to mimic each other and fail. Despite falling short initially, Gulick said that the combination could still be used if other options prove unsuccessful. The new guidelines reflect the broad choice in AIDS treatment, listing the pr os and cons for each, while suggesting that doctors and patients pick a regimen that best fits their needs.

While at present there are more than 20 HIV drugs that fall under four broad categories, with an almost infinite number of combinations, the best regimens suggested are those that attack the disease from different angles.
'"/>




Related medicine news :

1. Tetanus causing toxin has therapeutic properties
2. Mice model to study bacterial therapeutic pathway
3. Hormone regimen and how recently used may determine cancer risk
4. Protective regimen for acute Graft-versus-host disease
5. Distraction therapy found very effective in postoperative patients
6. Antioxidants found in chocolates
7. Hidden influenza virus protein found
8. Scientists found ancient Human Germ Killer
9. Chewing gum found to increase brainpower
10. Ulcer causing bug found in stored food
11. Antioxidants found in chocolates
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... 19, 2017 , ... The American College of Lifestyle ... recently formed Corporate Roundtable, a group of individuals and organizations whose collective vision ... Canyon Ranch is a unique collection of lifestyle-based immersion vacation settings and programs ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets ... (published by Xlibris on July of 2014). This book details the recent advances and ... approaches that benefit people who have lost all of their natural teeth . ...
(Date:9/19/2017)... Va (PRWEB) , ... September 19, 2017 , ... The ... the use of health IT to create efficiencies in healthcare information exchange and a ... the release of their latest industry white paper, entitled Barriers to Adoption of ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of ... successfully concluded its meeting with the U.S. Food and ... insulin formulation. At ... regulatory pathway for submission of ORMD-0801, would be a ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
(Date:8/29/2017)... 2017 In a move that promises to ... for veterinary practices of all sizes, Cubex LLC and ... makes TITAN,s expertise in physical security, drug diversion investigations, ... nationally. "Every ... substances is at risk today," said TITAN founder and ...
Breaking Medicine Technology: